What Comes Next for the BIOSECURE Act? Dan Kracov Shares Insights on Fierce Pharma’s “The Top Line” Podcast
October 7, 2024
Dan Kracov, chair of the firm’s Life Sciences Industry practice, was recently featured on Fierce Pharma’s “The Top Line” podcast episode, “Breaking down BIOSECURE—Industry implications and what comes next.”
Kracov addressed the wider implications of the pending BIOSECURE Act, which would prohibit U.S. companies utilizing the services and equipment of certain Chinese companies from maintaining contracts with the U.S. government due to national security concerns. He also analyzed some of the steps life sciences companies are currently taking in response to the legislation and the concessions that might be necessary to satisfy lawmakers from both parties.
